Syracuse

Clinical evaluation of subcutaneous administration of cefepime

Archive ouverte

Pilmis, B. | Mizrahi, A. | Petitjean, G. | Le Monnier, A. | El Helali, N.

Edité par CCSD ; Elsevier Masson -

International audience. Objectives. – Cefepime is a fourth-generation cephalosporin active against Pseudomonas aeruginosa andmost Enterobacteriaceae. Intravenous (IV) administration is the standard route of prescription. However,subcutaneous administration (SC) may represent an interesting alternative. We aimed to evaluate SCadministration of cefepime versus the IV route in geriatric patients.Patients and methods. – Multicenter retrospective analysis in patients treated with cefepime by SC routewho underwent plasma concentration monitoring.Results. – Twelve patients were included in the SC group and matched to 12 patients in the IV group.The median and mean Cmin levels were 29.05 mg/L [14.2–48.2]; 33.4 mg/L (± 21.8) in the SC groupand 31.9 mg/L [26.5–51.7]; 39.6 mg/L (± 27) (P = NS) in the IV group. No local SC administration-relatedcomplications were reported. No relapse was observed over six months of follow up.Conclusion. – Subcutaneous use of cefepime seems to have the same clinical and microbiological effectiveness as parenteral administration.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion